Kornimate/medical-research-clean huggingface dataset:
endobronchial cryotherapy in management of mebo in patients with inoperable nsclc

Conditions: Non Small Cell Lung Cancer; Non-Small Cell Carcinoma of Lung, TNM Stage 4; Bronchogenic Cancer

Summary: background: in end-stage patients when all management options have been used, will often develop compromise of their airways as the cancer continues to progress. endobronchial therapy options may help to relieve some of their symptoms, allowing improvement in their shortness of breath as they go home in combination with other palliative therapies. objective: to compare the safety ; efficacy; and clinical outcome of endobronchial cryotherapy combined with chemotherapy and/ or radiotherapy versus chemo-radiotherapy alone on patients with non small cell lung cancer. patients and method(s): a prospective randomized clinical trial was carried out on 60 patients with different ages of both sexes, diagnosed as bronchogenic carcinoma non-small cell lung cancer type (nsclc) . the patients attended the hospital in the chest department, qena faculty of medicine, south valley university. assessment of the patients was done and randomly assigned into two groups. group1 ,include 30 patients subjected to chemotherapy , radiotherapy and endobronchial cryotherapy.group 2 , include include 30 patients subjected to chemotherapy and radiotherapy alone.


Eligibility criteria:
inclusion criteria: * all cases with pathologically proved and inoperable nsclc cases based on tumor position; in the main and subsegmental bronchi. exclusion criteria: * cases with severe respiratory distress, uncorrectable impaired bleeding profile and prechemotherapy.

Keywords: non-small cell lung cancer (nsclc) cryotherapy chemoradiotherapy
jaw, mouth and bone health, and quality of life in children with juvenile idiopathic arthritis (jia)

Conditions: Arthritis, Juvenile

Summary: the norwegian jia study (norjia) is a prospective, longitudinal, multicenter, observational study of 250 children with juvenile idiopathic arthritis (jia) and 250 healthy controls, attending the three norwegian university clinics in bergen, tromsø, or trondheim. the study will run over 5 years, and include extensive clinical, laboratory, radiological and oral examinations at baseline and after 2 years follow-up. there will be a special focus on the jaw (temporomandibular joints) with extensive imaging and clinical examination, aiming at establishing scoring systems for active and chronic disease and growth disturbances. another focus is to study mouth and teeth problems, such as caries and gingivitis, and look for predictors of poor oral health in children with jia compared to health peers. as chronic inflammation, reduced physical activity and certain anti-inflammatory drugs can be detrimental for bone strength and development, the investigators also want to study the bone health of children with jia, and look for predictors of poor bone mineral density. the results of the study may contribute to better diagnostics of inflammatory processes, earlier detection of poor oral or bone health, and thereby point to possible prevention strategies to increase quality of life for children with jia in the future.


Eligibility criteria:
inclusion criteria: * fulfilling the ilar criteria for juvenile idiopathic arthritis exclusion criteria: * no consent

Keywords: temporomandibular joint oral health bone & bones bone density quality of life
study on the prevalence of human papillomavirus types in women >= 15 years of age in the kingdom of saudi arabia

Conditions: Infections, Papillomavirus; Cervical Cancer

Summary: this study aims to determine the prevalence of human papillomavirus (hpv) and to assess the hpv type distribution among women \>= 15 years of age, attending routine gynaecological examination in the kingdom of saudi arabia.


Eligibility criteria:
inclusion criteria: * subjects/subjects' parents or guardians, who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study, * women \>=15 years of age attending a clinic for routine cervical screening, * written informed consent obtained from the subject and/or subject's parent/guardian. exclusion criteria: * referral for abnormal cervical sample at the current visit, * abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed, * no cervical sample provided, * history of hysterectomy, * known diagnosis of immunosuppression, or patient on immunosuppressives, * pregnant female \>=25 years of age.

Keywords: human papillomavirus
restoring skill in walking

Conditions: Mobility Limitation

Summary: the purpose of the study is to examine the effect of an intervention to improve walking based on motor learning (skill-based) compared to the usual intervention (strength, flexibility and balance-based) on clinical, psychological and laboratory measures of walking and balance of older adults with mobility disability (walking problems).

while therapeutic exercise to improve mobility and balance appears to improve physical performance and may reduce falls, less is known about the responsiveness to specific interventions or the relation between response to intervention and the underlying problems or impairments. therapeutic approaches for improving mobility and reducing fall risk are heterogeneous, but do not consistently focus on problem solving as a method of enhancing motor control or skill, an approach that has been found to be important for motor learning in animal models. this two-year pilot study will allows us to compare the clinical, psychological and laboratory outcomes after a motor-learning based and an impairment-targeted exercise intervention to improve walking in older adults. all subjects will participate in pre and post intervention testing and a 12 week exercise intervention for gait involving either a motor learning (skill enhancement) or impairment-targeted (lower extremity strengthening, flexibility and gait cues).

Eligibility criteria:
inclusion criteria: * 65 years of age and older * ambulatory (with or without a straight cane, and without the assistance of another person) * have written approval/clearance of their physician to participate in low to moderate intensity, supervised exercise as is characteristic of the interventions for improving gait. * difficulty with walking or balance as indicated by the following two criteria during baseline testing: * mild to moderate slowing of walking speed (walking speed ≥ .6m/s and ≤ 1.0m/s) and, * gait variability (step length coefficient of variability, cv \> 4.5%, or step width cv \ 30%)

Keywords: gait impairment
topical use of corticosteroid to prevent epiretinal membrane following retinal tear

Conditions: Epiretinal Membrane

Summary: in this prospective randomized controlled double blind pilot clinical study, we aim to assess whether administration of a topical corticosteroid would attenuate epiretinal membrane formation following development of retinal tears treated with laser retionpexy.

epiretinal membrane (erm) is a frequent, sight-threatening eye condition occurring in 1.02% - 28.9% of eyes in persons aged 40 years or older. \[1\] while often idiopathic in nature, erm formation has been associated with retinal tears, possibly due to a breakdown of the blood-retinal barrier \[1-3\]. pathological analysis of erm content shows inflammatory mediators such as cytokines, growth factors and interleukins, which can promote fibroblast remodelling that leads to a contractile scar formation on the retinal surface. \[1, 4-8\] for this reason, erm formation has been suggested to be an aberrant tissue repair or wound-healing process driven by inflammatory reactions. since corticosteroids inhibit the inflammatory cascade and fibroblast transdifferentiation, administration of a corticosteroid following retinal tears should theoretically reduce the risk of erm formation. \[9-10\] in this study, we aim to assess whether administration of a topical corticosteroid would attenuate erm formation following laser retinopexy of retinal tears.

Eligibility criteria:
inclusion criteria: * between ages 18 to 80 (inclusive) * english-speaking * undergoing non-pneumatic laser retinopexy procedure for horseshoe retinal tear (without retinal detachment) exclusion criteria: * patient refusal or delay of retinopexy procedure for more than 48 hours after diagnosis * patients who are pseudophakic or aphakic * medical conditions contraindicated with prednisolone: viral diseases of the cornea and conjunctiva including herpes simplex, vaccinia, varicella; fundal diseases of ocular structures; mycobacterial infections; hypercortisolism. * previous history of epiretinal membrane, retinal surgery (cryo or laser) * patients with hypersensitivity or contraindication for corticosteroids (viral diseases of the cornea and conjunctiva including herpes simplex, vaccinia, varicella; fungal diseases of ocular structures; mycobacterial infections; hypercortisolism).
clinical trial of quadrivalent influenza virus split vaccine

Conditions: Influenza

Summary: to evaluate the immunogenicity and safety of 2 doses of quadrivalent influenza virus split vaccine in healthy population aged 6-35 month., so as to provide a data support for phase iii clinical trials.


Eligibility criteria:
inclusion criteria: * healthy infants aged 6-35 months. * volunteer legal guardian or client informed consent, voluntarily participate in and sign informed consent. * the volunteer legal guardian or client has the ability (non-illiterate) to understand the study procedures, to use a thermometer, scale, and fill in a diary card as required, and be able to complete the clinical study in compliance with the clinical trial protocol. exclusion criteria: * the underarm body temperature on the day of enrollment was \> 37.0℃. * have been suffering from influenza within the previous 3 months (confirmed by either clinical, serological or microbiological methods). * any previous influenza vaccination (registered or experimental) within 6 months or any planned influenza vaccination during the study period. * allergic to any component of the vaccine, a history of allergic reactions to eggs or gentamicin sulfate. * a history of severe allergy to any vaccine or drug. * preterm birth (delivered before 37 weeks of gestation), low birth weight baby (birth weight \< 2300g for girls, \<2500g for boys). * dystocia, asphyxia rescue, nervous system damage history; * congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. * acute illness, severe chronic illness or acute attack of chronic disease on the day of vaccination; * a history of live attenuated vaccination within 14 days prior to vaccination and a history of other vaccinations within 7 days prior to vaccination; * patients who received immunoenhancement or inhibitor therapy within 3 months (continued oral or intravenous administration for more than 14 days); * congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; * history of asthma, past two years of instability requiring emergency treatment, hospitalization, intubation, oral or intravenous administration of corticosteroids; * have received blood or blood-related products; * a history of convulsion, epilepsy, encephalopathy, guillain-barre syndrome, a history of mental illness or a family history; * a history of abnormal coagulation function (such as coagulation factor deficiency, coagulation disease); * planning to relocate before the end of the study or to leave for an extended -period during the scheduled study visit; * participating in or planning to participate in other clinical trials in the near future; * the investigators determined that any conditions were inappropriate to participate in the clinical trial.
a study to evaluate tour006 in patients with chronic kidney disease and elevated hs-crp

Conditions: Chronic Kidney Diseases; Chronic Kidney Insufficiency; Chronic Renal Diseases; Chronic Renal Insufficiency; Kidney Insufficiency, Chronic; C-Reactive Protein; High Sensitivity C-Reactive Protein; Hs-CRP; hsCRP

Summary: this study will evaluate the safety, tolerability, pharmacokinetics, and crp-lowering effect of quarterly and monthly subcutaneous administration of tour006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-crp.

previous clinical studies have suggested that il-6-driven inflammation plays a key role in the pathogenesis of cardiovascular diseases including atherosclerotic cardiovascular disease (ascvd) and heart failure. this phase 2 study will evaluate the safety, tolerability, pharmacokinetics, and crp-lowering effect of quarterly and monthly subcutaneous administration of tour006, a fully human monoclonal antibody against il-6. tour006 binds the il-6 cytokine and inhibits downstream il-6 signaling, thereby reducing the pharmacodynamic marker, hs-crp.

Eligibility criteria:
inclusion criteria: * age ≥18 years at time of icf signature. * serum hs-crp level ≥2.0 mg/l and \<15 mg/l * diagnosis of chronic kidney disease, egfr ≥15 and \ 200 mg/g * received covid-19 vaccine at least 30 days prior to the screening visit, per participant verbal attestation. * agreement to comply with contraception and reproduction restrictions exclusion criteria: * clinical evidence or suspicion of active infection * current or recent covid-19 infection within 30 days * serious infection within 6 months or more than 1 such episode within 18 months * any history of a serious opportunistic infection within 18 months * known history of immunodeficiency * history of gastrointestinal ulceration or perforation within 12 months * history of active diverticulitis, active inflammatory bowel disease, or gi abscess within 12 months * history of gi bleeding requiring hospitalization and/or transfusion within 6 months * new york heart association class iii or iv congestive heart failure and/or hospitalization for heart failure exacerbation within 6 months * acute coronary syndrome, stroke, transient ischemic attack, or other thrombotic or thromboembolic event, or arterial revascularization procedure within 6 months

Keywords: interleukin-6 il-6 il6 interleukin-6 inhibitors anti-interleukin-6 agents anti-inflammatory agents antiinflammatory agent antiinflammatory agents agents, antiinflammatory anti-inflammatory agent
a study of mk-0869 (aprepitant) and mk-0517 (fosaprepitant) in pediatric participants receiving chemotherapy (mk-0869-134)

Conditions: Chemotherapy-Induced Nausea and Vomiting

Summary: this study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.

fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after intravenous administration; the pharmacological effect of fosaprepitant is attributed to aprepitant. the birth to one year old cohort will be initiated in parts iii and iv upon completion of part ii (steps a and b) in participants \<6 months of age.

Eligibility criteria:
inclusion criteria: * is 0 (at least 37 weeks gestation) to 17 years of age * is scheduled to receive moderately to highly nausea-inducing chemotherapy or participant did not tolerate a previous chemotherapy regimen that is planned to be repeated * is expected to receive ondansetron * female participants who have begun menstruating must have a negative pregnancy test * weighs ≥3.0 kg if \ 6 months of age, and ≥7.5 kg if \> 2 years of age * has a pre-existing venous catheter exclusion criteria: * uses any illicit drugs or abuses alcohol * is pregnant or breast feeding * has a symptomatic central nervous system (cns) tumor * has an infection or other uncontrolled disease other than cancer * has known history of heart qt wave prolongation
metabolomics study on intensive care acquired muscle weakness in polytrauma

Conditions: Metabolomics; Critical Care; Critical Illness; Critical Illness Myopathy; Critical Illness Polyneuropathy; Intensive Care (ICU) Myopathy; Muscle Weakness

Summary: in this mono-center pilot trial, polytrauma patients admitted to intensive care will be included. investigators are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing. aim of the study is to investigate (1) changes of the blood metabolome in patients with icuaw (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for icuaw or can be used as marker for icuaw.


Eligibility criteria:
inclusion criteria: * acute polytrauma patient * age ≥ 18 years old * expected intensive care stay ≥ 3 days * american society of anesthesiologists classification i or ii exclusion criteria: * patient had received cardiopulmonary resuscitation * limitation of therapy or comfort care

Keywords: pilot trial muscle biopsy blood metabolome
gi neuromuscular pathology prospective registry

Conditions: Gastroparesis

Summary: in this research study, biopsy samples will be collected to provide more insight into the underlying cause of the motility disorders, help direct further investigation into the cause of the underlying condition, provide future prognosis and predict response to gastric electrical stimulation (ges).

biopsies will be collected from patients that have been diagnosed with gastroparesis (having nausea, retching, bloating and fullness of stomach) and are undergoing surgery for the ges implantation. these patients will serve as our study group population. biopsy samples of those who do not have gastroparesis but are undergoing surgery on the digestive system will be collected after the patients consent to be on the trial. these patients will serve as our control group population. detailed medical history will be collected and the study group patients will be asked to complete two questionnaire to assess the severity of the symptoms. they will be followed in the clinic at 6, 12, 18 and 24 months post implantation.

Eligibility criteria:
inclusion criteria study group: patients who are undergoing surgical full-thickness biopsy of the stomach and/or proximal jejunum for the clinical evaluation of gi neuromuscular disorder. inclusion criteria control group: patients undergoing esophagectomy, sleeve gastrectomy for obesity, or roux-en y gastric bypass patients undergoing whipple surgery patients undergoing transplant surgery patients who are organ donors and undergoing surgery exclusion criteria study group: contraindication for surgical full-thickness biopsy for any reason. significant comorbidity due to severe cardiovascular, renal, pulmonary, or liver disease. significant coagulopathy non-ambulatory patients: bed-ridden, nursing home resident. pregnant unable to give own informed consent prisoners exclusion criteria control group: prior diagnosis of gastroparesis prior diagnosis of chronic intestinal pseudo-obstruction unable to give own informed consent if not an organ donor

Keywords: nausea vomiting functional dyspepsia bloating regurgitation retching
acellular matrix from human dermis in combination with orthobiologic stimuli for augmentation of massive rotator cuff tears

Conditions: Rotator Cuff Tears

Summary: the use of biologic acellular matrices for the surgical augmentation of rotator cuff lesions has greatly expanded inrecent years. the study team patented a method for removing cells from human dermis (acellular dermal matrix), maintaining unaltered biological and structural integrity. acellular dermal matrix has been succesfully used for rotator cuff surgical repair augmentation beside in a limited number of patients. the aim of the project is to demonstrate the therapeutical efficacy of this strategy in patients affected by rotator cuff massive tears. acellular dermal matrix will be also combined with autologous orthobiologics.


Eligibility criteria:
inclusion criteria: * patients affected by large to massive lesion according to gerber involving supraspinatus and infraspinatus tendons * tendon retraction \<=3 according to thomazeau * fatty degeneration \<=3 according to goutallier * possibility to obtain tendon reduction, * pre-operative magnetic resonance imaging, * ability to read, understand and complete outcome scores exclusion criteria: * patients affected by osteoarthritic degeneration, * frozen shoulder, * symptomatic acromioclavicular arthritis, * revision surgeries, * inability to cope with post-operative rehabilitation regimen, * autoimmune connective tissue disease, * current or past hematologicaldisorders, * comorbidities affecting healing, * active infections, * cancers, * pregnancy and lactation
swiss liver venous thrombosis study

Conditions: Observational Study

Summary: the liver venous thrombosis study is a prospective observational cohort study aimed at collecting clinical data, patient reported outcomes and biological samples of all patients who have been newly and previously diagnosed with liver venous thrombosis in one of the participating hospitals in- and out-patient clinics of the participating centers in switzerland. all new patients diagnosed with liver venous thrombosis or patients who are currently being treated in one of the participating centers, will be asked to participate in the study.

background outcome measures: primary: liver venous thrombosis recanalization secondary: thrombosis progression, overall mortality, major bleeding, ascites objective * to start a prospective observational cohort study of liver venous thrombosis patients in switzerland from their primary diagnosis and already diagnosed patients. * to examine long-term medical outcomes in patients with liver venous thrombosis in switzerland by defining incidence, risk factors and treatment results * to prospectively collect data on medical history, serious comorbidities, baseline clinical parameters, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, hospital stays, interventions and complications. * to store in a biobank blood and biological samples, obtained during routine practice methods n/a

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * admitted in hospital or attend outpatient clinic * objectively confirmed portal vein thrombosis and/or hepatic vein thrombosis * budd-chiari-syndrome (bcs), non-cirrhotic intrahepatic portal hypertension (nciph), sinusoidal obstructive syndrome (sos), other vascular diseases (hepatoportal sclerosis (hc), nodular regenerative hyperplasia (nrh), obliterative portal venopathy (opv) or idiopathic portal hypertension (iph)) * subjects willing to provide informed consent exclusion criteria * thrombosis limited to mesenteric or splenic vein * inability to sign consent form * follow-up not possible * cardiovascular, tumoral, pulmonary comorbidity with life expectancy estimated to be less than 6 months * portal vein invasion by hepatocellular carcinoma